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Purpose of review: Non-coding RNA (ncRNAs), such as microRNAs (miRNAs) and 
long non-coding RNAs (LncRNAs), are becoming fundamentally important in the 
pathophysiology relating to injury-induced vascular remodelling. We highlight recent 
studies that demonstrate the involvement of ncRNAs in vein graft disease, in in-stent 
restenosis (ISR) and in pulmonary arterial hypertension (PAH), with a particular focus 
on endothelial cell (EC) and vascular smooth muscle cell (VSMC) function. We also 
briefly discuss the emerging role of exosomal-derived ncRNAs and how this 
mechanism impacts on vascular function.  
Recent findings: NcRNAs have been described as novel regulators in the 
pathophysiology of vascular injury, inflammation and vessel wall remodelling. In 
particular, several studies have demonstrated that manipulation of miRNAs can 
reduce the burden of pathological vascular remodelling. Such studies have also shown 
that exosomal miRNA-mediated, cell-to-cell communication between ECs and 
VSMCs is critical in the disease process. In addition to miRNAs, lncRNAs are 
emerging as regulators of vascular function in health and disease. Although lncRNAs 
are complex in both their sheer numbers and mechanisms of action, identifying their 
contribution to vascular pathology is essential.  
Summary: Given the important roles of ncRNAs in vascular injury and remodelling 
together will their capacity for cell-to-cell communication, manipulating ncRNA 
might provide novel therapeutic interventions.  
Keywords: Non-coding RNA, Vascular remodelling, in-stent restenosis, vein graft, 
pulmonary arterial hypertension 
 
Introduction 
 
Vascular remodelling after acute injury is a multifactorial pathological process that 
contributes to cardiovascular disease, including ISR, PAH, atherosclerosis, and others 
[1, 2]. The remodelling process involves structural changes of the vessel as a 
consequence of altered cell proliferation/growth, cell apoptosis/death, cell migration, 
and modulation of the production and degradation of extracellular matrix (ECM) [3, 
4]. Both endothelial and smooth muscle cells are key mediators of the pathological 
response to acute vascular injury, driving the progressive remodelling process that 
characterizes neointimal formation [5, 6]. In addition, inflammatory activation of the 
vessel wall also contributes to vascular remodelling [7]. Endothelial injury, such as 
the endothelial denudation that arises after implantation of stents into coronary vessels, 
is an important early contributor to the initiation of vascular inflammation [8]. 
Following injury, growth factors and cytokines released from ECs and inflammatory 
cells promote smooth muscle cell proliferation, migration and ECM protein 
deposition [9, 10]. Although multiple studies over the last two decades have focused 
on delineating the molecular mechanisms that drive the remodelling response to 
vascular injury [11-13], with the exemption of drug-eluting stents, there is currently a 
paucity in effective therapeutics, necessitating further research and innovative 
thinking around molecular mechanisms that might govern pathological responses 
       According to recent transcriptome analyses, protein-coding genes actually 
account for only 1.5%-2.0% of the human transcriptome. The transcriptional output of 
the larger portion of the transcriptome (i.e. ~ 98%) consists of non-coding RNA 
species, including miRNAs (< 200nt) and LncRNAs >200nt [14]. MiRNAs have been 
intensively studied for the last decade [15, 16], However, lncRNA structure and 
function is an emerging field in the vascular arena, with the publication of several 
studies recently that suggest an important contribution to pathological vascular 
remodelling processes. 
 
MiRNA biogenesis and function 
MiRNAs are a novel class of endogenous, small/short non-coding transcripts of 
16 to 29 nucleotides in length RNA that negatively regulate gene expression via 
degradation or translational inhibition of their target mRNAs. The biogenesis of 
miRNA is well reviewed in several highly cited publications [17-19]. MiRNAs are 
regarded as essential regulators in physiology and pathophysiology of the 
cardiovascular system [20, 21]. They are becoming an intriguing target for therapeutic 
intervention for a number of reasons. First, a single miRNA can regulate several 
hundred target genes (including targets in the same or complimentary cellular 
pathways) making miRNAs potentially very powerful disease modifiers [22]. Second,  
several lines of evidence demonstrate that miRNAs are essential regulators of VSMC 
development, differentiation, and contractile function offering a rich repertoire of 
disease-modifying therapeutics [23]. Finally, RNA therapeutics benefit from a great 
deal of prior translational research (e.g. SiRNA and exon skipping technology) that 
suggest RNA therapeutics might be attractive, albeit with specific challenges such as 
delivery, off target effects etc. [24]. 
The role of miRNAs in pathological vascular remodelling 
Neointimal formation is a hallmark of many vascular diseases. VSMCs are 
one of the major cellular components of the vessel wall and are implicitly involved in 
neointimal formation [25]. For example (and aligned to our own research) in vein 
graft disease, VSMC proliferation and migration contributes to the increased vein 
graft medial thickening, neointimal formation and superimposed atherosclerosis [26]. 
Similarly, the proliferation of VSMC in response to vascular injury following 
angioplasty and stent implantation leads to neointimal formation and restenosis [27]. 
Further, a key feature of PAH is pulmonary vascular remodelling and development of 
occlusive and plexiform intimal lesions in the small, distal pulmonary vessels [28]. In 
this section, we discuss recent findings on the regulation of pathological vascular 
remodelling by miRNAs.  
MiR-21 first identified to be significantly increased in rat carotid arteries 
following balloon injury [29]. In VSMCs, knockdown of miR-21 inhibited cell 
proliferation, decreased migration and induced apoptosis by targeting important 
regulators of cellular function, including PTEN and Bcl-2 [29], PDCD4 and activator 
protein 1 [30], tropomyosin 1 [31], while overexpression of miR-21 induced human 
aortic SMC proliferation and reduced VSMC differentiation by targeting specificity 
protein-1 (SP1) [32]. Landmark studies also showed that miR-21 is involved in the 
regulation of TGF-β and BMP signalling, activation of which led to increased 
expression of miR-21 via post-transcriptional mechanisms [33, 34]. These signalling 
pathways are central mediators of the vascular remodelling process following acute 
injury, regulating VSMC proliferation, migration, and phenotype [35]. Similar to the 
Ji et al study described above, upregulation of miR-21 has been observed across many 
in vivo models of vascular injury, including mouse and pig models of vein graft 
failure, and mouse models of ISR [29] [36] [37**] [38**].  These studies also 
underlined the therapeutic potential of targeting this broadly-expressed miRNA, 
showing that pharmacological inhibition of miR-21 could decrease neointimal 
formation in injured rat carotid arteries following angioplasty, while anti-miR-21 
coated stents effectively reduced ISR by inhibiting VSMC proliferation following 
implantation [29] [38**]. Consistent with these findings, genetic ablation of miR-21 
significantly reduced neointimal formation in a mouse vein graft failure model[36] 
and blocked neointimal formation in a mouse model of ISR by reducing VSMC 
proliferation and migration, macrophage polarization, and inflammatory 
activation[37**]. Mechanistic studies have identified several target genes of miR-21, 
suggesting complex mechanism of action dictated by both expression across a range 
of cell types and targeting transcriptome within those cells in a dynamic, 
pathologically regulated manner [36-38**]. In addition, the expression of miR-21 in 
plasma samples from patients with ISR following implantation of drug-eluting stents 
were significantly higher than in non-ISR patients and healthy controls, which 
showed that miR-21 could act as a potential biomarker for the development of ISR 
[39].  In PAH, manipulation of miR-21 levels has also been shown to affect the 
vascular remodelling that leads to the formation of obstructive lesions in the 
pulmonary vasculature. Sequestration of miR-21 by antimiR-21 treatment diminished 
chronic-hypoxia-induced pulmonary hypertension (PH) and attenuated pulmonary 
vascular remodelling [40]. However, miR-21 knockout mice displayed exaggerated 
manifestations of PH in SU5416 and chronic hypoxia models [41*, 42]. This data, 
while conflicting, highlights the complex role that miR-21 might play in vascular 
remodelling in the distal vasculature in the lung.  Further studies are now required to 
identify the mechanisms underlying these divergent phenotypes, potentially by 
exposing miR-21 conditional knockout animals to different experimental PAH 
induction protocols, or by utilising novel strategies to inhibit miR-21 in situ.  The 
role of miR-21 in PAH has been extensively reviewed elsewhere [43]. In a 
translational context, manipulation of miR-21 in different pre-clinical disease models 
has shown positive therapeutic effects, although it would be important to develop 
strategies for localised targeting of the miR-21 inhibitors to the vessel wall, such as in 
the case of eluting stents. Interestingly, a chemically modified oligonucleotide 
antimiR-21 manufactured by Regulus Therapeutics (San Diego, CA92121, United 
States) has entered phase 1 clinical trials for the treatment of Alport Syndrome, a 
disease of the glomerular basement membrane, where miR-21 inhibition is aimed at 
targeting abnormal renal function [44].  
        In addition to miR-21, several other miRNAs have been shown to play 
critical roles in the pathological response to acute vascular injury. MiRNAs have been 
shown to mediate the effects of many known regulators of vascular disease, such as 
PDGF, TGF-β/BMP, and the interleukin family of inflammatory cytokines. For 
example, miR-146b-5p is necessary for PDGF-induced VSMC phenotype transition 
[45].  MiRNAs that control vascular functions by affecting TGF-β family signalling 
have been reviewed elsewhere [46]. MiRNAs also play a central role in the 
modulation of vascular cell behaviour and function during disease pathogenesis, such 
as Let-7a and miR-221in vein graft disease [47] [48], the miR-143/145 cluster in ISR 
and PAH [49] [39] [50**] and miR-30c [51], miR-322 [52], miR-130a [53] in PAH. 
An overview of confirmed target genes for these miRNAs are showed in Table 1.  
In summary, many miRNAs are now known to be associated with the 
development of vascular remodelling processes in vivo and in vitro, while 
manipulation of several miRNAs have shown therapeutic efficacy in animal models 
of vascular disease. However, many facets of miR biology remain to be fully 
elucidated, including their precise mechanisms of action, cell selectivity in effect and 
the factors underlying their diverse effects.  Moreover, as previously stated, there is 
currently a lack of effective pharmacological strategies for the direct targeting of 
miRNA in disease pathogenesis. Thus, much works remains to be done to fully 
understand, target and therapeutically manipulate the biological roles of miRNAs in 
vascular disease.  
 
LncRNA transcription and function 
        LncRNAs, in common with mRNAs, are generally transcribed by RNA 
Polymerase II, and further spliced, 5’-capped (m7G), and 3’-polyadenylated [54]. The 
transcriptional regulation of lncRNA is well reviewed elsewhere [55]. LncRNA are, in 
general, expressed at relatively low levels and are far less well conserved than 
miRNA [56-58]. LncRNA can be classified into different subtypes based on their 
genomic location: sense lncRNAs, antisense lncRNAs, bidirectional lncRNAs, 
intronic lncRNAs and intergenic lncRNAs [59]. LncRNAs have diverse molecular 
mechanisms of regulating gene expression through interactions with DNA, RNA, or 
protein, by acting as decoys, scaffolds, guides or signalling molecules (Figure 1). In 
addition, lncRNAs can regulate gene expression post-transcriptionally, for example by 
modulating splicing, mRNA translation and mRNA degradation, or by acting as 
miRNA sponges. There are several comprehensive reviews summarized the functions 
and mechanisms of lncRNA [55, 60-63]. 
Role of lncRNAs in vascular remodelling 
Accumulating early evidence suggests that lncRNAs may play an important 
role in vascular pathophysiology. Early studies identified antisense noncoding RNA in 
the INK4 locus (ANRIL), a lncRNA expressed in VSMC, which was able to regulate 
CDKN2A/B expression in aortic VSMC and attenuate proliferation in atherosclerosis 
[64-66] as well as modulate inflammatory responses in coronary artery disease [67]. 
Lnc-Ang362, which hosts the miR-221 and miR-222 genes, was shown to be 
regulated by angiotensin II in VSMC, and was in turn able to modulate VSMC 
proliferation, vascular remodelling and neointimal hyperplasia in concert with 
miR-221 and miR-222 [68-70]. These studies showed that lncRNA were involved in 
the control of cell proliferation, and could be regulated alongside proximal miRNAs 
in VSMCs. RNA-Seq analysis of human coronary artery SMC revealed a novel 
lncRNA, Smooth muscle and Endothelial cell-enriched 
migration/differentiation-associated long NonCoding RNA (SENCR), which is 
expressed in both VSMCs and ECs In VSMCs, knockdown of SENCR decreased the 
expression of myocardin and numerous smooth muscle contractile genes and 
increased a number of pro-migratory genes (namely Midkine (MDK) and Pleiotrophin 
(PTN)). Inhibition of these two genes reversed the increased VSMC migration 
mediated by SENCR silencing, which suggested that the expression of these genes 
was partially regulated by SENCR in these cells. However, the functions of SENCR 
in endothelial cells were not reported in this study [71*]. Our group further revealed 
that SENCR induced the proliferation, migration and angiogenesis of Human 
Umbilical Vein Endothelial Cells (HUVECs). In patient samples, SENCR expression 
was altered in vascular tissues and cells derived from patients with critical limb 
ischemia and premature coronary artery disease compared with healthy controls [72]. 
These two studies revealed that SENCR could modulate the behaviour of both SMC 
and EC, and exhibited altered expression patterns in vascular tissues and cells from 
vascular disease patients. However, the exact molecular targets and mechanisms of 
SENCR in pathological vascular remodelling remain to be determined.  
Similar to SENCR, LincRNA-p21 is expressed in both VSMC and EC. In 
human VSMCs, lincRNA-p21 repressed cell proliferation and induce apoptosis in 
vitro. LincRNA-p21 also inhibited neointimal formation in carotid arteries and 
repressed proliferation and induced apoptosis in carotid artery injury model in vivo. 
The authors further confirmed the expression level of lincRNA-p21 was decreased in 
patients with coronary heart disease [73**]. In mouse EC, lincRNA-p21 induced cell 
apoptosis and cell cycle progression. In addition, lincRNA-p21 inhibited cell 
proliferation through binding miR-130b [74]. Unlike many lncRNAs, LincRNA-p21 
contains a very highly conserved 780 nt length 5’ region in mammals, which provided 
the possibility of using an in vivo animal model to study the role of this lncRNA [75]. 
These data identified lincRNA-p21 is a key regulator of cell proliferation and 
apoptosis in vascular cells, which are primary contributors to vascular remodelling. 
Consistent with the human in vitro data, knockdown of lincRNA-p21 resulted in 
dramatic neointimal hyperplasia in a mouse model of carotid artery injury, which 
indicated that lincRNA-p21 could serve as therapeutic target to treat vascular 
remodelling diseases [73**].  
Using RNA-Seq, we recently defined a novel smooth muscle specific lncRNA 
SMILR, which could be induced by IL-1α and PDGF in human saphenous vein 
smooth muscle cells (HSVSMCs). Knockdown of SMILR markedly reduced 
HSVSMC proliferation, likely through regulation of the HAS2 gene, located proximal 
to the genetic locus for SMILR. In human samples, SMILR expression increased in 
unstable atherosclerotic plaques and plasma from patients with high plasma 
C-reactive protein [76**]. These data suggested that inhibiting SMILR expression 
could be a potential target for treating vascular diseases characterised by VSMC 
proliferation.  
In the context of EC, studies have shown that the lncRNA Metastasis 
associated lung adenocarcinoma transcript 1 (MALAT1) could regulate retinal vessel 
remodelling by affecting retinal EC proliferation, migration and tube formation, as 
genetic ablation of MALAT1 inhibited the proliferation of EC and reduced neonatal 
retina vascularization in vivo [77, 78**]. In human aortic EC, knockdown of the 
lncRNA H19 reduced cell proliferation and activated p21/CDKN1A, increasing 
apoptosis, decreasing angiogenesis, and diminishing the number of cells in G0/G1 and 
S phases in cell cycle [79]. These two lncRNAs that are highly expressed in EC 
showed multifunctional features both in vivo and in vitro. EC lncRNAs have been also 
reviewed elsewhere [80-82]. An overview of target genes/miRNAs of these lncRNAs 
is given in Table 1.  
In summary, there are few lncRNAs that have been studied in depth in the 
context of vascular disease, with most studies simply reporting the dysregulation of 
vascular cell function after manipulation of the lncRNAs. The direct targets and 
mechanisms of many lncRNA remain largely unknown, so urgent attention is needed 
in this context, particular relating to their mechanism of action. Unfortunately, the low 
conservation of many lncRNAs restricts the availability of in vivo disease models, 
which is a significant impediment to translation of lncRNA therapeutics to the clinical 
arena. Therefore, much more work is required to fully explore the role of lncRNAs in 
the pathophysiological processes driving vascular disease, sometimes using 
innovative models with human cells and tissues.  
 
Vascular cell-to-cell communication through miRNAs  
       Cell-to-cell communications can be mediated by extracellular vesicles, 
exosomes, apoptotic bodies, microparticles, and tunnelling nanotubes (TNTs) [83, 84]. 
Exosomes are 40 to 100nm in size and represent a specific subtype of secreted 
membrane vesicles formed through the fusion of multivesicular endosomes with the 
plasma membrane [85]. Exosomes are released by many types of cell, and have been 
identified in most body fluids, including plasma, urine, saliva, cerebrospinal, amniotic 
and synovial fluids. Exosomes are now known to carry a wide array of molecules 
including: proteins, DNAs, mRNAs, miRNAs and lncRNAs, depending on a variety 
of factors including the cell type from which the exosome originates, the state of 
health of the host, and extracellular stimuli [86]. Exosomes can be taken up by 
neighbouring or distant cells and can be functional in the recipient cells by fusion 
with the plasma membrane, via receptor-mediated uptake or by internalisation via 
endocytosis or macropinocytosis [87]. Since the discovery of miRNA in exosomes, a 
number of studies have focused on the identification and function of exosomal 
miRNAs in cancer [88] and cardiovascular diseases [89-93]. Interestingly, cancer cell 
derived exosomes contain key components of miRNA biogenesis including the 
proteins RNA-induced Silencing Complex (RISC), Argonaute-2 (AGO2), Dicer, and 
TAR RNA-binding protein (TRBP), which displayed cell-independent capacity to 
process precursor miRNAs into mature miRNAs [94]. Here we focus on the role of 
exosomal miRNAs in vascular cells.  
An early study showing the importance of exosomal miRNAs in vascular cells 
evaluated exosomal miR-143/145 in atherosclerosis. This study showed that 
miR-143/145 can affect vascular cell function following exosomal transport, via 
cell-to-cell communication. Kruppel like factor 2 (KLF2) or shear-stimulated 
HUVECs secreted miR-143/145 enriched exosomes, which could be taken up by 
VSMCs to derepress the targets genes of miR-143/145 (such as EST 
domain-containing protein Elk-1 (ELK1), Krupple like factor 4 (KLF4), Matrix 
metallopeptidase 3 (MMP3), Slingshot protein phosphtase 2 (SSH2)) and induce an 
atheroprotective SMC phenotype both in vitro and in vivo [95]. In the pulmonary 
vasculature, we recently found that exosomal miR-143 derived from pulmonary artery 
smooth muscle cells (PASMCs) can be transferred to pulmonary artery endothelial 
cells (PAECs) exerting pro-migratory and pro-angiogenic effects [50**]. Apart from 
exosome-mediated transfer, TGF-β triggered miR-143/145 transfer to ECs from 
VSMCs via TNTs. Over-expression of miR-143/145 in ECs had anti-angiogenic 
effects and reduced EC proliferation by directly targeting hexokinase 2 (HKII) and 
Integrin beta-8 (ITGβ8) separately [96**]. These data demonstrated the vital role of 
miR-143/145 in vascular cell proliferation, migration, and angiogenesis. Other EC 
secreted miRNAs including miR-126 that could be taken by VSMCs via 
Ago2-facilitated miRNA transmission [97], miR-26a [98*] and miR-214 [99]. The 
cell-to-cell communication between vascular cells by miRNAs is summarised in 
Figure 2. This is a relatively new field and there is much to discover about miRNA 
regulation and function through secretion and cell: cell communication. 
Exosomal lncRNAs have been found in several cancer cells and patient 
plasma. These include lncRNA HOX transcript antisense RNA (HOTAIR) [100], H19 
[101], Long intergenic Non-coding RNA, Regulator Of Reprogramming (lncRNA 
ROR) [102], Linc-very-low-density lipoprotein receptor (Linc-VLDLR) [103], 
lncRNA transcript UC.339 (lncRNA TUC339) [104], lncRNA-p21 [105] and other 
lncRNAs [106]. However, there is no report about exosomal lncRNAs secreted by the 
vascular cells. Recently, our group demonstrated that smooth muscle enriched 
lncRNA Smooth muscle enriched long noncoding RNA (SMILR) was secreted into 
the cell culture media but was located in a non-exosomal or microparticle fraction 
[76**]. More studies should be performed to investigate the secretory pathways 
utilised by this lncRNA, the function of the secreted lncRNA molecules and the 
compartment or fraction that the lncRNA is located within.  More generally, it would 
be important to identify whether cell-cell communication mediated by exosomal or 
microparticle lncRNAs plays a role in regulating the behaviour of vascular cells 
during vascular remodelling processes. 
 
Therapeutic prospective of ncRNAs 
The translation of ncRNAs from bench to bedside has received considerable attention 
in recent years. In general, the therapeutic approaches involve the inhibition or 
overexpression of ncRNAs. Several approaches to manipulate ncRNAs are currently 
in use pre-clinically, including miRNA antagonists, miRNA mimics, antisense 
oligonucleotide (ASO), and small interfering RNA (siRNA). The first anti-miRNA 
(Miravirsen) to enter clinical trials is a locked nucleic acid-modified DNA 
phosphorothioate antisense oligonucleotide targeting miR-122, which sequesters 
mature miR-122 to treat patients with hepatitis C. Miravirsen is currently in phase 2 
clinical trials [107, 108]. MiR-RX34 (MRX34), a double-stranded miR-34 RNA 
mimic encapsulated in a liposomal nanoparticle formulation, is the first miRNA 
mimic to enter phase I clinical trials [109]. Several antimiRNA/mimic therapeutics 
targeting miRNAs are currently under development, including Let-7, miR-21, 
miR-208, miR-195, miR-221, miR-29, miR-155, miR-10b, and miR-103/107. Four of 
these miRNA-based therapeutic drugs have entered into phase 1 clinical trials 
[110-114*]. Despite intensive studies of miRNAs in vascular disease, there is no 
miRNA-based therapeutics entering clinical trials at present in this area. One of the 
obstacles impeding development of miRNA-based therapeutics is low delivery 
efficacy to the vasculature and the likely need for repeated delivery. There are several 
strategies to deal with miRNA-based therapeutic challenges, which are summarised 
and discussed in this review [114*]. However, despite the obstacles, pharmacological 
manipulation of disease-associated miRNAs shows promising therapeutic potential in 
animal disease models. With more and intensive studies of miRNAs in vitro and in 
vivo pre-clinical models and human patients, the application of miRNA-based 
therapeutics in the clinic can become a reality. For lncRNAs, there are also several 
obstacles facing the development of lncRNA-based therapeutics. First, the functions 
and mechanisms used by lncRNAs are much more complex and diversified than 
miRNAs [115]. In spite of recent studies, lncRNAs are still largely an “unknown” 
with regard to their cellular functions and molecular mechanisms. Second, the 
majority of lncRNAs that localise to the nucleus are thought to act as epigenetic 
regulators [116]. This feature makes it hard to target lncRNAs using siRNA, which is 
a potential therapeutic strategy. Third, most lncRNAs lack conservation between 
species, which restricts the utility of pre-clinical disease models. One possible 
strategy to overcome these issues is to identify the direct targets of disease-associated 
lncRNAs and use pre-clinical disease models to assess the therapeutic role of these 
targets in disease pathogenesis and/or use innovative human-based model systems ex 
vivo and in vitro.  
 
Conclusions 
Recent studies have dramatically improved our understanding of the multifaceted 
roles that ncRNAs play in pathological vascular remodelling. The expression of 
several miRNAs have been shown to be dysregulated in various animal disease 
models as well as in patient samples, while novel direct targets of these 
disease-associated miRNAs have been validated. Manipulation of these miRNAs in 
pre-clinical animal models has showed therapeutic benefit. However, there are still 
some less-understood aspects of miRNA biology that require further study, for 
example the role(s) of miRNA passenger strands (which in some cases have been 
shown to be functional), in vivo targeting (as most targeted studies of miRNAs are 
carried out in vitro) and miRNA: miRNA or miRNA: lncRNA interactions. Compared 
with miRNAs, only few LncRNAs have been investigated in depth in vascular disease. 
The cellular function and biological mechanisms utilised by these lncRNAs still 
requires further exploration. Taken together, the evidence summarised in this review 
reveals that targeting ncRNAs may be a promising therapeutic strategy for the 
treatment of diseases characterised by vascular remodelling.  
 
Key points 
• Noncoding RNAs have emerged as critical regulators of diseases characterised 
by pathological vascular remodelling. 
• MiRNAs have been shown to regulate VSMC proliferation, migration, apoptosis 
and phenotype switching.  
• Accumulating studies indicate that lncRNAs may critically regulate vascular 
pathophysiology. Deep sequencing will identify more lncRNAs involved in the 
regulation of vascular cell behaviour and disease pathogenesis.  
• Exosomal miRNAs from vascular cells play an important role during the 
development of atherosclerosis and PAH by regulating SMC and EC function.  
• Based on extensive studies in pre-clinical models of vascular disease and in 
patient samples, several clinical trials using various approaches to manipulate 
ncRNA (e.g. anti-miRNAs, miR mimics) are now in progress.    
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Table 1 Overview of confirmed target genes of ncRNAs in VSMCs  
ncRNA      Target genes          Effect on cell behaviour/neointimal formation  
miR-21         PTEN[29, 38**], BCL2[29]       VSMC proliferation and apoptosis  
               PDCD4[30, 37**]              VSMC apoptosis, proliferation, and migration 
               TPM1[31]                  VSMC proliferation and migration 
               SP1[32]                    VSMC proliferation and differentiation 
               DOCK4,5,7[35]             VSMC migration and contractility 
STAT3[36, 37**],PTEN,  
BMPR2[36]                VSMC proliferation, migration; modulates neointimal formation  
               BMPR2, STAB1, YOD1[40]   PASMC proliferation and apoptosis 
miR-221        CDKN1B[48]              VSMC proliferation; modulates neointimal formation 
miR-30c        PDGFRβ[51]               PASMC proliferation and apoptosis       
miR-322        BMPR1α, Smad5[52]         PASMC proliferation and migration   
 
BMPR2 indicates bone morphogenetic protein receptor 2; PTEN, phosphatase and tensin homologue; 
BCL2, B-cell lymphoma 2; PDCD4, programmed cell death 4; TPM1, tropomyosin 1 (Alpha); SP1, 
specificity protein 1; DOCK4,5,7, dedicator of cytokinesis 4,5,7; STAT3, signal transducer and 
activator of transcription 3; STAB1, stabilin-1; YOD1, YOD1 deubiquitinase; CDKN1B, 
cyclin-dependent kinase inhibitor 1B; PDGFRβ, beta-type platelet-derived growth factor receptor; 
BMPR1α, bone morphogenetic protein receptor type 1α; CDKN1A, cyclin-dependent kinase inhibitor 
1A; MDM2, E3 ubiquitin-protein ligase Mdm2; and HAS2, hyaluronan synthase 2. 
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Figure Legends 
 
Figure 1: Overview of the genome location and functions of lncRNAs 
(A). Based on their genome locations, lncRNAs can be classified into Sense: 
transcribed from the sense strand of a protein-coding gene; Antisense: transcribed 
from the antisense strand of a protein-coding gene; Intronic: transcribed entirely from 
an intron of a protein-coding gene; Intergenic: transcribed sequences is not located 
near any other protein-coding loci; Bidirectional: transcribed sequences are located on 
the opposite strand from a protein-coding gene whose transcription is initiated less 
than 1000 base pairs away. (B). The main functions of lncRNA including 
SIGNALLING: lncRNA can function as molecular signal or indicator of 
transcriptional activity; DECOY: lncRNAs can preclude the access of regulatory 
proteins to DNA; GUIDES: lncRNA are be required for the localisation of specific 
protein complexes either in cis (on neighbouring genes) or in trans (on distantly 
located genes); SCAFFOLDS: lncRNAs can serve as adaptors to bring two or more 
proteins into discrete complexes.  
 
Figure 2: Cell-to-cell communication between vascular smooth muscle and 
endothelial cells through miRNAs 
Working models were showed to illustrate cell-to-cell communication between 
VSMCs and ECs. (A). Various stimuli induce exosomal miR-143 secretion in 
PASMCs, which can be taken up by EC to induce cell migration and angiogenesis 
[50**]. (B). Shear stress can induce KLF2 and miR-143/145 expression and inhibit 
miR-126 expression in EC. MiR-143/145 and miR-126 transfer to VSMCs through 
exosomes, and Ago2-facilitated miRNA transmission affects target genes and cellular 
functions in VSMCs, leading to atheroprotective phenotype [95, 97]. (C). TGF-β 
induced miR-143 expression in VSMCs, which can be transferred to ECs through 
TNTs to inhibit target gene expression and induce cell proliferation and angiogenesis 
[96].  (D). MiR-206 binding to 3’UTR of ARF6/NCX1 in EC inhibits exosomal 
miR-26a secretion and uptake into VSMCs, where they regulate the SMC contractile 
phenotype [98].   
 
 
 
Table 1 Overview of confirmed target genes of ncRNAs in VSMCs  
 
BMPR2 indicates bone morphogenetic protein receptor 2; PTEN, phosphatase and tensin homologue; 
BCL2, B-cell lymphoma 2; PDCD4, programmed cell death 4; TPM1, tropomyosin 1 (Alpha); SP1, 
specificity protein 1; DOCK4,5,7, dedicator of cytokinesis 4,5,7; STAT3, signal transducer and 
activator of transcription 3; STAB1, stabilin-1; YOD1, YOD1 deubiquitinase; CDKN1B, 
cyclin-dependent kinase inhibitor 1B; PDGFRβ, beta-type platelet-derived growth factor receptor; 
BMPR1α, bone morphogenetic protein receptor type 1α; CDKN1A, cyclin-dependent kinase inhibitor 
1A; MDM2, E3 ubiquitin-protein ligase Mdm2; and HAS2, hyaluronan synthase 2. 
ncRNA      Target genes          Effect on cell behaviour/neointimal formation  
miR-21         PTEN[29, 38**], BCL2[29]       VSMC proliferation and apoptosis  
               PDCD4[30, 37**]              VSMC apoptosis, proliferation, and migration 
               TPM1[31]                  VSMC proliferation and migration 
               SP1[32]                    VSMC proliferation and differentiation 
               DOCK4,5,7[35]             VSMC migration and contractility 
STAT3[36, 37**],PTEN,  
BMPR2[36]                VSMC proliferation, migration; modulates neointimal formation  
               BMPR2, STAB1, YOD1[40]   PASMC proliferation and apoptosis 
miR-221        CDKN1B[48]              VSMC proliferation; modulates neointimal formation 
miR-30c        PDGFRβ[51]               PASMC proliferation and apoptosis       
miR-322        BMPR1α, Smad5[52]         PASMC proliferation and migration   
miR-130        CDKN1A[53]               PASMC proliferation      
Lnc-Ang362     miR-221, mi-222[68]         VSMC proliferation 
LincRNA-p21    MDM2[73**]              VSMC proliferation and apoptosis; modulates neointimal formation 
SMILR         HAS2[117]                  VSMC proliferation 
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